ReviewMolecular biology reports2026
Mechanometabolic endothelial senescence as a translational framework for cardiometabolic vascular disease and vascular ageing.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cardiometabolic vascular disease (CMVD) is used in this Review as an operational umbrella for vascular injury arising from interacting metabolic, renal and cardiovascular stress, rather than as a universally standardised diagnosis. We examine mechanometabolic endothelial senescence as a framework linking local haemodynamic vulnerability with systemic cardiometabolic load. Evidence from human vascular tissue, clinical vascular-function studies, animal models, flow-controlled systems and endothelial-cell experiments indicates that low or oscillatory shear, matrix stiffness, hyperglycaemia, dyslipidaemia, uraemic and hepatic stress, inflammation and oxidative injury can converge on DNA-damage responses, p53/p21 and p16/pRB signalling, NAD⁺-sirtuin decline, mitochondrial dysfunction, metabolic rewiring and chromatin regulation. Biological sex modifies this framework: endothelial function declines across the menopause transition, whereas direct human arterial evidence suggests that senescence-associated endothelial dysfunction may differ between women and men; however, sex-disaggregated mechanistic data remain sparse. Clinically, flow-mediated dilatation, carotid-femoral pulse-wave velocity, coronary flow reserve and the index of microcirculatory resistance provide compartment-specific functional anchors, but none is a direct senescence assay. Evidence in heart failure with preserved ejection fraction, chronic kidney disease and metabolic dysfunction-associated steatotic liver disease remains heterogeneous and is strongest in preclinical or mixed translational studies. We therefore propose a staged validation strategy combining endothelial identity, convergent senescence markers, circulating-cell or extracellular-vesicle measures, vascular function and organ-specific outcomes. Mechanometabolic endothelial senescence is best viewed as a context-dependent disease amplifier and testable translational model, not a universal primary cause.
Indexed as
Identifiers
42848089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.